.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK08_Bexagliflozin.Bexagliflozin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK08_Bexagliflozin.Bexagliflozin| name: | Bexagliflozin | |
| ATC code: | A10BK08 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 20 | mg |
| volume of distribution: | 300 | L |
| clearance: | 14.7 | L/h |
| other parameters in model implementation | ||
Bexagliflozin is a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor used for the treatment of type 2 diabetes mellitus to improve glycemic control. It is an oral antidiabetic agent that promotes urinary glucose excretion; it received FDA approval in June 2023 and is approved for clinical use.
Pharmacokinetic parameters are reported for healthy adult subjects following single oral administration under fasting conditions.